scholarly journals Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma

2020 ◽  
Vol 48 (7) ◽  
pp. 030006052093605 ◽  
Author(s):  
Chen Tian ◽  
Zehui Chen ◽  
Yueyang Li
Keyword(s):  
Bone Marrow ◽  
B Cell ◽  
Young Patients ◽  
B Cell Lymphoma ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Chop Regimen ◽  
Large B Cell Lymphoma ◽  
Primary Bone ◽  
Primary Bone Marrow

Primary bone marrow diffuse large B cell lymphoma (DLBCL) is an independent pathologic type with a poor prognosis when treated with standard chemoimmunotherapy. Generally, rituximab-based high-dose chemotherapy regimens such as dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) can be administered to young patients, followed by autologous stem cell transplantation. For elderly patients, the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) regimen is well tolerated, but it is an insufficient induction therapy for this group. Herein, we reported an elderly patient diagnosed with primary bone marrow DLBCL, germinal center B-cell-like subtype. Considering tolerance, the R-CHOP regimen was administered. However, his disease progressed after two treatment cycles. Then, the rituximab, gemcitabine, dexamethasone, cisplatin, lenalidomide regimen was administered, but the patient still experienced disease progression. Subsequently, the histone deacetylase (HDAC) inhibitor chidamide and Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib were concurrently administered, and the patient achieved complete remission. We found that the response of primary bone marrow DLBCL to chemotherapy was poorer than that of de novo DLBCL. High-dose chemotherapy regimens such as DA-EPOCH should be administered to young patients in combination with rituximab. For elderly patients, new targeted drugs such as HDAC and BTK inhibitors appear to produce favorable outcomes.

scholarly journals Long-Term Remission of Primary Bone Marrow Diffuse Large B-Cell Lymphoma Treated with High-Dose Chemotherapy Rescued byIn VivoRituximab-Purged Autologous Stem Cells

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Hiroshi Kazama ◽  
Masanao Teramura ◽  
Kentaro Yoshinaga ◽  
Akihiro Masuda ◽  
Toshiko Motoji
Keyword(s):  
Bone Marrow ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Large B Cell Lymphoma ◽  
Primary Bone ◽  
Primary Bone Marrow ◽  
Large B Cell

Primary bone marrow diffuse large B-cell lymphoma (DLBCL) is a rare type of extranodal lymphoma with poor prognosis. Here, we report a case of primary bone marrow DLBCL successfully treated with high-dose chemotherapy and rescued byin vivorituximab-purged autologous stem cells. A 39-year-old woman visited our hospital because of anemia. Bone marrow examination revealed a large B-cell lymphoma invasion. An18F-fluorodeoxyglucose positron emission tomography scan revealed disseminated bone marrow uptake without evidence of dissemination at other sites. These findings led to a diagnosis of primary bone marrow DLBCL. Our patient underwent R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy and achieved complete remission. Subsequently, she received high-dose chemotherapy with anin vivorituximab-purged autologous stem cell transplant. Seven years have passed since the transplantation, and she remains in remission. This suggests that transplantation of anin vivorituximab-purged autograft is a promising strategy for primary bone marrow DLBCL.

Primary bone marrow diffuse large B cell lymphoma: a case series and review

2010 ◽  
Vol 90 (7) ◽  
pp. 791-796 ◽  
Author(s):  
Hung Chang ◽  
Yu-Shin Hung ◽  
Tung-Liang Lin ◽  
Po-Nan Wang ◽  
Ming-Chung Kuo ◽  
...  
Keyword(s):  
Bone Marrow ◽  
B Cell ◽  
Cell Lymphoma ◽  
Case Series ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Primary Bone ◽  
Primary Bone Marrow ◽  
Large B Cell

scholarly journals Aggressive CD5-Positive Primary Bone Marrow Diffuse Large B-Cell Lymphoma with Leukemic Presentation

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Mark G. Evans ◽  
Sherif A. Rezk ◽  
Lauren C. Pinter-Brown ◽  
Xiaohui Zhao
Keyword(s):  
Bone Marrow ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Intrathecal Methotrexate ◽  
Non Hodgkin Lymphoma ◽  
Large B Cell Lymphoma ◽  
Primary Bone ◽  
Primary Bone Marrow ◽  
Large B Cell

Primary bone marrow diffuse large B-cell lymphoma is an exceedingly rare form of non-Hodgkin lymphoma. It may demonstrate a leukemic presentation, and a proportion of cases have CD5 expression. The prognostic implications of this CD5-positivity remain unknown. Here, we present a 78-year-old man who presented with circulating peripheral blood lymphoma cells and a hypercellular marrow involved by diffuse large B-cell lymphoma, germinal center B-cell subtype. The patient responded favorably to six cycles of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) and intrathecal methotrexate. He unfortunately relapsed in several enlarged inguinal lymph nodes and succumbed to the lymphoma approximately one year after diagnosis, demonstrating the particularly aggressive clinical course of his disease.

scholarly journals Fever and arthralgia as the initial symptoms of primary bone marrow diffuse large B-cell lymphoma: A case report

2016 ◽  
Vol 11 (5) ◽  
pp. 3428-3432 ◽  
Author(s):  
SAISAI REN ◽  
YANLING TAO ◽  
LU JIA ◽  
PANPAN CHENG ◽  
JILEI ZHANG ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Case Report ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Initial Symptoms ◽  
Primary Bone ◽  
Primary Bone Marrow ◽  
Large B Cell

A Case of Primary Bone Marrow Diffuse Large B-cell Lymphoma Presenting with Polyarthritis

2016 ◽  
Vol 23 (4) ◽  
pp. 256
Author(s):  
In-Young Kim ◽  
Dam Kim ◽  
Byeong Bae Park ◽  
Woong-Soo Lee ◽  
Ji-Young Choi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Primary Bone ◽  
Primary Bone Marrow ◽  
Large B Cell

PO44 Primary bone marrow diffuse large B cell lymphoma: a case report

2012 ◽  
Vol 82 ◽  
pp. S25
Author(s):  
A. Escriva Vicedo ◽  
A. Tolosa ◽  
J. Ros Soto ◽  
A. Garcia Feria ◽  
M.J. Cejalvo Andújar ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Case Report ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Primary Bone ◽  
Primary Bone Marrow ◽  
Large B Cell

scholarly journals Triple-Hit Expression of MYC, BCL-2, and BCL-6 in a Primary Bone Marrow Large B-Cell Lymphoma

2014 ◽  
Vol 142 (suppl_1) ◽  
pp. A128-A128
Author(s):  
Ming Xie ◽  
James Huang ◽  
Xia Chen ◽  
Elizabeth Wey ◽  
Mark Micale
Keyword(s):  
Bone Marrow ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Primary Bone ◽  
Primary Bone Marrow ◽  
Large B Cell

Primary Mediastinal B-Cell Lymphoma: A Review of Pathology and Management

2001 ◽  
Vol 19 (6) ◽  
pp. 1855-1864 ◽  
Author(s):  
Koen van Besien ◽  
Mohammed Kelta ◽  
Pranay Bahaguna
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Young Patients ◽  
B Cell Lymphoma ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Medline Search ◽  
Large B Cell Lymphoma ◽  
Phase Ii Studies ◽  
Large B Cell

PURPOSE: Primary mediastinal B-cell lymphoma (PMBL) is recognized as a separate disease entity in the REAL classification. There is uncertainty about the relevance and especially the optimal management of this disorder. In this review, we discuss clinical presentation, pathology, pathobiology, and management of PMBL in order to provide a platform for initiation of further clinical and biologic studies. MATERIALS AND METHODS: Studies were identified through a MEDLINE search and from the bibliographies of relevant articles. RESULTS: PMBL is a tumor of young adults who present with a rapidly proliferating tumor. At diagnosis, the tumor is usually limited to intrathoracic organs. Spread to parenchymal organs such as liver, kidneys, and CNS is common at recurrence. Fibrosis and the presence of so-called clear cells are distinctive morphologic features of PMBL, although they are not pathognomonic or even necessary for diagnosis. On the other hand, biologic features relating to oncogene rearrangement and overexpression as well as cytogenetic features clearly differentiate PMBL from other types of diffuse large B-cell lymphoma. Phase II studies and retrospective series indicate cure rates that range from 38% to 88%. The role of chemotherapy, radiation, and high-dose chemotherapy with stem cell rescue in the management of PMBL is reviewed. CONCLUSION: PMBL has unique clinical and biologic characteristics that are radically different from those of other types of diffuse large B-cell lymphoma. Although relatively rare, its aggressive growth and its occurrence in young patients increase the clinical relevance of this entity. The consistent recognition and study of PMBL will allow the development of new approaches to its management.

Sign in / Sign up

Export Citation Format

Share Document